RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsLesslpes29:
My motives for posting are to try & balance out the hard core bashing team.
i hold a lot of Onc shares & regardless of company results, activity or lack of same, readers need to be aware of the realities. Not some loss leader waste of time.
About 8/10 posts I refer back to the corporate web site. That is public information & vetted by
lawyers, FDA overseeing & other procedural check points.
Since my motives are to point out the achievements of Onc,
I take zero offence to any personal attacks or banter around what I post.
I have over the years negotiated with presidents of companies. Sat on a multi million $ pension advisory board. Been a director on two other boards.
My point. I'm not offended, bothered or even blink @ the silliness out of a few on this site or others.
Back to my point.
The recent company presentation is worth a read for those who do not know the details of ONCs mission & progress.
The mission, is razor sharp. To get Pelareorep approved as a cancer treatment.
Most recent news 2 weeks ago, they approached FDA for a meeting to discuss parameters for the upcoming MBc phase 3 trial.
Next catalysts?
Great question. My guess would be something around the Roche Gobblet trial & the advancement of the pancreatic phase 3 trial.
Other than that, there are 3-5 ongoing less discussed trials.
The AGM , I think early May? The formal updates. Quarterly AGM etc , U.S. usually are insignificant.
As any business changing events would be reported through SEDAR & other news media.
A partership, buyout or other business development of importance would be announced to everyone at the same time.
" meetings" , " chats," " conferences " are not going to be launching pads for major progress, unless a formal N.R. First.
So, we wait.